Midazolam (po) |
Cmax (ng mL-1) |
n |
20 |
20 |
20 |
20 |
20 |
|
|
Estimated ratio after inverse logarithmic conversion |
— |
1.65 |
1.86 |
1.08 |
1.09 |
|
|
90% CI of the ratio |
— |
1.45 – 1.87 |
1.64 – 2.11 |
0.95
– 1.22 |
0.96 – 1.23 |
|
|
p-value |
— |
<.0001 |
<.0001 |
0.3214 |
0.2820 |
|
AUC0-t (ng h mL-1) |
n |
20 |
20 |
20 |
20 |
20 |
|
|
Estimated ratio after inverse logarithmic conversion |
— |
2.69 |
3.07 |
1.12 |
1.08 |
|
|
90% CI of the ratio |
— |
2.47 – 2.94 |
2.81 – 3.35 |
1.02
– 1.22 |
0.98 – 1.17 |
|
|
p-value |
— |
<.0001 |
<.0001 |
0.0400 |
0.1778 |
Prednisolone (po) |
Cmax (ng mL-1) |
n |
20 |
20 |
20 |
20 |
19 |
|
|
Estimated ratio after inverse logarithmic conversion |
— |
0.87 |
0.89 |
0.96 |
0.87 |
|
|
90% CI of the ratio |
— |
0.82 – 0.92 |
0.84 – 0.95 |
0.91-
1.02 |
0.82 – 0.92 |
|
|
p-value |
— |
0.0001 |
0.0017 |
0.2643 |
0.0002 |
|
AUC0-t (ng h mL-1) |
n |
20 |
20 |
20 |
20 |
19 |
|
|
Estimated ratio after inverse logarithmic conversion |
— |
1.04 |
1.11 |
1.00 |
0.98 |
|
|
90% CI of the ratio |
— |
1.01 – 1.08 |
1.08 – 1.15 |
0.97
– 1.04 |
0.94 – 1.01 |
|
|
p-value |
— |
0.0471 |
<.0001 |
0.9269 |
0.2537 |
Atorvastatin (po) |
Cmax (ng mL-1) |
n |
20 |
19 |
19 |
19 |
19 |
|
|
Estimated ratio after inverse logarithmic conversion |
— |
1.00 |
1.24 |
1.06 |
1.02 |
|
|
90% CI of the ratio |
— |
0.81 – 1.22 |
1.01 – 1.52 |
0.87
– 1.30 |
0.83 – 1.25 |
|
|
p-value |
— |
0.9651 |
0.0853 |
0.6236 |
0.8932 |
|
AUC0-t (ng h mL-1) |
n |
20 |
19 |
19 |
19 |
19 |
|
|
Estimated ratio after inverse logarithmic conversion |
— |
1.75 |
2.10 |
1.13 |
1.15 |
|
|
90% CI of the ratio |
— |
1.64 – 1.87 |
1.97 – 2.24 |
1.06
– 1.20 |
1.08 – 1.23 |
|
|
p-value |
— |
<.0001 |
<.0001 |
0.0033 |
0.0006 |
Midazolam (iv) |
AUC0-t (ng h mL-1) |
n |
20 |
19 |
19 |
19 |
19 |
|
|
Estimated ratio after inverse logarithmic conversion |
— |
1.40 |
1.53 |
1.16 |
1.11 |
|
|
90% CI of the ratio |
— |
1.30 – 1.50 |
1.43 – 1.64 |
1.08
– 1.24 |
1.03 – 1.19 |
|
|
p-value |
— |
<.0001 |
<.0001 |
0.0009 |
0.0207 |